Fig. 4From: Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaSurvival data for 127 patients with CMML stratified by the Mayo prognostic model and the Molecular Mayo model. (a) Median survivals using the Mayo Prognostic Model were not reached, 26Â months, and 15Â months. (b) Median survivals using the Molecular Mayo Model were not reached, 70Â months, 26Â months and 11Â monthsBack to article page